Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment
- PMID: 16245220
Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment
Abstract
Background/aims: Despite a proposed role of oxidative stress in the pathogenesis of nonalcoholic steatohepatitis, antioxidant approaches have not been investigated sufficiently in the therapy of nonalcoholic steatohepatitis. Our aim was to determine whether vitamin E plus C therapy is effective in normalization of liver enzymes compared to ursodeoxycholic acid treatment in patients with fatty liver disease.
Methods: This was an open-labeled, prospective, randomized study enrolling patients with histologically proven fatty liver disease who had chronically elevated alanine aminotransferase, despite a three-month reducing diet. Patients consuming alcohol (more than 20 g/day) were excluded. The patients were randomly prescribed either oral vitamin E (600 IU/day) plus vitamin C (500 mg/day) or ursodeoxycholic acid (10 mg/kg/day). Patients were randomized as two groups to receive vitamin E plus vitamin C combination (28 patients, 10 F) or ursodeoxycholic acid treatment (29 patients, 13 F).
Results: There was no significant change in body mass index before and after the treatment in both groups. At the end of six months of therapy, serum aspartate aminotransferase and aminotransferase levels significantly decreased in both treatment options. Vitamin E and C combination was more efficacious on serum aminotransferase levels than ursodeoxycholic acid, but the difference was not significant. Alanine aminotransferase decreased to normal levels in 17 of 27 (63%) and in 16 of 29 patients (55%), respectively, in the two groups. Gamma-glutamyl transpeptidase decreased in patients receiving ursodeoxycholic acid, but no change was obtained in the vitamin-treated patients.
Conclusions: Vitamin E plus C combination treatment is a safe, inexpensive and effective treatment option in patients with fatty liver disease, with results comparable to those obtained with ursodeoxycholic acid. Since more effective new therapeutic options are lacking, patients with fatty liver disease should be encouraged to take vitamin E and C supplements, which are safe and affordable.
Similar articles
-
A randomized double-blind study of the short-time treatment of obese patients with nonalcoholic fatty liver disease with ursodeoxycholic acid.Braz J Med Biol Res. 2003 Jun;36(6):723-9. doi: 10.1590/s0100-879x2003000600007. Epub 2003 Jun 3. Braz J Med Biol Res. 2003. PMID: 12792701 Clinical Trial.
-
Combined ursodeoxycholic acid and glycyrrhizin therapy for chronic hepatitis C virus infection: a randomized controlled trial in 170 patients.Eur J Gastroenterol Hepatol. 1999 Oct;11(10):1077-83. doi: 10.1097/00042737-199910000-00002. Eur J Gastroenterol Hepatol. 1999. PMID: 10524635 Clinical Trial.
-
Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin e in nonalcoholic steatohepatitis.Clin Gastroenterol Hepatol. 2006 Dec;4(12):1537-43. doi: 10.1016/j.cgh.2006.09.025. Clin Gastroenterol Hepatol. 2006. PMID: 17162245 Clinical Trial.
-
Ursodeoxycholic acid for nonalcoholic steatohepatitis.Eur J Gastroenterol Hepatol. 2012 Nov;24(11):1247-53. doi: 10.1097/MEG.0b013e3283572ec0. Eur J Gastroenterol Hepatol. 2012. PMID: 22864259 Review.
-
Review article: Drug therapy for non-alcoholic fatty liver disease.Aliment Pharmacol Ther. 2006 Jan 15;23(2):207-15. doi: 10.1111/j.1365-2036.2006.02751.x. Aliment Pharmacol Ther. 2006. PMID: 16393299 Review.
Cited by
-
Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials.Diabetologia. 2012 Apr;55(4):885-904. doi: 10.1007/s00125-011-2446-4. Epub 2012 Jan 27. Diabetologia. 2012. PMID: 22278337
-
Multidisciplinary pharmacotherapeutic options for nonalcoholic Fatty liver disease.Int J Hepatol. 2012;2012:950693. doi: 10.1155/2012/950693. Epub 2012 Dec 9. Int J Hepatol. 2012. PMID: 23304532 Free PMC article.
-
Antioxidant vitamins in the context of nonalcoholic fatty liver disease in obese children and adolescents.Rev Paul Pediatr. 2013 Dec;31(4):523-30. doi: 10.1590/S0103-05822013000400016. Rev Paul Pediatr. 2013. PMID: 24473959 Free PMC article. Review.
-
The Role of Vitamin E in the Treatment of NAFLD.Diseases. 2018 Sep 24;6(4):86. doi: 10.3390/diseases6040086. Diseases. 2018. PMID: 30249972 Free PMC article. Review.
-
The endoplasmic reticulum as a potential therapeutic target in nonalcoholic fatty liver disease.Curr Opin Investig Drugs. 2008 Oct;9(10):1084-8. Curr Opin Investig Drugs. 2008. PMID: 18821470 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical